用於測定肝細胞癌(HCC)患者的治療的有效響應的生物標記

• 收藏
• 分享

专利权人:

BAYER PHARMA AKTIENGESELLSCHAFT

发明人:

KRISSEL, HEIKO,PHLER, FLORIAN,JEFFERS, MICHAEL

申请号：

HK15107187.1

公开号：

HK1206611A

申请日:

2015.07.28

申请国别(地区):

HK

年份:

2016

代理人:

摘要：

This invention is directed to the use of one or more biomarkers defined as KRAS or NRAS gene for predicting the pharmaceutical efficacy or clinical response of MEK protein kinase inhibitor and/or Sorafenib or Regorafenib to be administered to a Hepatocellular carcinoma (HCC) patient. Further the invention is directed to in-vitro methods for identifying mutated-type KRAS or NRAS gene in HCC patient and kits thereof.

来源网站：

中国工程科技知识中心

来源网址：

http://www.ckcest.cn/home/